HCP
HTGM

Hexagon Capital Partners’s HTG Molecular Diagnostics, Inc. Common Stock HTGM Stock Holding History

Hexagon Capital Partners’s Portfolio HTGM Stock Details HTGM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-4
Closed – – 808
2020
Q4 		$0 Buy
+4
New +$233 ﹤0.01% 769

Other funds holding HTGM

CPA
Cowen Prime Advisors New York $290M AUM 57.8% 1-Year Est. Return
SC
Samjo Capital New York $254M AUM 36.81% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
ACM
AIGH Capital Management Baltimore, Maryland $733M AUM 327.32% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BWLSA
Blue Water Life Science Advisors Larkspur, California $125M AUM 91.82% 1-Year Est. Return
WVP
Worth Venture Partners Fort Lee, New Jersey $31.6M AUM 28.5% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Squarepoint
Squarepoint New York $85.1B AUM 20.93% 1-Year Est. Return

Hexagon Capital Partners's HTGM Position: Q1 2021 in Review

Hexagon Capital Partners sold out of HTG Molecular Diagnostics, Inc. Common Stock (HTGM) in Q1 2021, closing a stake of 4 shares.

Hexagon Capital Partners first reported a position in HTGM in Q4 2020 and held it in 1 quarter. The position peaked at $0 in Q4 2020. 24 funds tracked by Wall St. Rank hold HTGM as of Q1 2021.

  • Hexagon Capital Partners reported no remaining HTG Molecular Diagnostics, Inc. Common Stock position as of Q1 2021 after selling out during the quarter.
  • Hexagon Capital Partners sold 4 HTG Molecular Diagnostics, Inc. Common Stock shares in Q1 2021.
  • Hexagon Capital Partners first reported a position in HTG Molecular Diagnostics, Inc. Common Stock in Q4 2020 and held it in 1 quarter.
  • Hexagon Capital Partners's HTG Molecular Diagnostics, Inc. Common Stock position peaked at $0 in Q4 2020.
  • 24 funds tracked by Wall St. Rank held HTG Molecular Diagnostics, Inc. Common Stock as of Q1 2021.

Based on Hexagon Capital Partners's 13F filing for Q1 2021, filed 13 May 2021.